5U7R

Identification of A New Class of Potent Cdc7 Inhibitors Designed by Putative Pharmacophore Model: Synthesis and Biological Evaluation of 2,3-Dihydrothieno[3,2-d]pyrimidin-4(1H)-ones

Summary for 5U7R

• Entry DOI: 10.2210/pdb5u7r/pdb
• Related: 5U7Q
• Descriptor: Rho-associated protein kinase 2, (1s,4s)-4-(4-fluorophenyl)-4-hydroxy-6'-(5-methyl-1H-pyrazol-4-yl)-1'H-spiro[cyclohexane-1,2'-thieno[3,2-d]pyrimidin]-4'(3'H)-one (3 entities in total)
• Functional Keywords: serine/threonine kinase, apo-protein, transferase
• Biological source: Homo sapiens (Human)
• Cellular location: Cytoplasm: O75116
• Total number of polymer chains: 4
• Total formula weight: 183316.50

Authors

Hoffman, I.D.,Skene, R.J. (deposition date: 2016-12-12, release date: 2017-03-29, Last modification date: 2024-03-06)

Primary citation

Kurasawa, O.,Oguro, Y.,Miyazaki, T.,Homma, M.,Mori, K.,Iwai, K.,Hara, H.,Skene, R.,Hoffman, I.,Ohashi, A.,Yoshida, S.,Ishikawa, T.,Cho, N.
Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones.
Bioorg. Med. Chem., 25:2133-2147, 2017

PubMed Abstract: Cell division cycle 7 (Cdc7) is a serine/threonine kinase that plays important roles in the regulation of DNA replication process. A genetic study indicates that Cdc7 inhibition can induce selective tumor-cell death in a p53-dependent manner, suggesting that Cdc7 is an attractive target for the treatment of cancers. In order to identify a new class of potent Cdc7 inhibitors, we generated a putative pharmacophore model based on in silico docking analysis of a known inhibitor with Cdc7 homology model. The pharmacophore model provided a minimum structural motif of Cdc7 inhibitor, by which preliminary medicinal chemistry efforts identified a dihydrothieno[3,2-d]-pyrimidin-4(1H)-one scaffold having a heteroaromatic hinge-binding moiety. The structure-activity relationship (SAR) studies resulted in the discovery of new, potent, and selective Cdc7 inhibitors 14a, c, e. Furthermore, the high selectivity of 14c, e for Cdc7 over Rho-associated protein kinase 1 (ROCK1) is discussed by utilizing a docking study with Cdc7 and ROCK2 crystal structures.

PubMed: 28284870
DOI: 10.1016/j.bmc.2017.02.021

Experimental method

X-RAY DIFFRACTION (3.33 Å)